Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Braconi, Chiara ^a   Swenson, Erica ^a   Kogure, Takayuki ^a   Huang, Nianyuan ^a   Patel, Tushar ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CAMPTOTHECIN; DILTIAZEM; FELODIPINE; FLUOROURACIL; GEMCITABINE; INTERLEUKIN 6; NIFEDIPINE; NITRENDIPINE; VERAPAMIL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; BIOINFORMATICS; CALCIUM TRANSPORT; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; GENE EXPRESSION; GENOME ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LC 50; MALE; MOUSE; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; BILE DUCT TUMOR; CANCER TRANSPLANTATION; CELL SURVIVAL; DNA MICROARRAY; DRUG DESIGN; GENE EXPRESSION REGULATION; IC 50; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BILE DUCT NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; DRUG DESIGN; FELODIPINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; INTERLEUKIN-6; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE;

EID: 78650718355     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015195     Document Type: Article

References (36)

1. Patel T (2006) Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 3: 33-42.
2. Khan SA, Miras A, Pelling M, Taylor-Robinson SD (2007) Cholangiocarcinoma and its management. Gut 56: 1755-1756.
3. Patel T (2001) Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33: 1353-1357.
4. Patel T (2002) Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2: 10.
5. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66.
6. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, et al. (2002) Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37: 806-813.
7. Singh P, Patel T (2006) Advances in the diagnosis, evaluation and management of cholangiocarcinoma. Curr Opin Gastroenterol 22: 294-299.
8. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, et al. (2004) Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101: 578-586.
9. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, et al. (2006) Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24: 3069-3074.
10. Baradari V, Hopfner M, Huether A, Schuppan D, Scherubl H (2007) Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol 13: 4458-4466.
11. Huether A, Hopfner M, Baradari V, Schuppan D, Scherubl H (2007) Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol 73: 1308-1317.
12. Cheon YK, Cho YD, Moon JH, Jang JY, Kim YS, et al. (2007) Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol 102: 2164-2170.
13. Sugawara H, Yasoshima M, Katayanagi K, Kono N, Watanabe Y, et al. (1998) Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma. Histopathology 33: 145-153.
14. Goydos JS, Brumfield AM, Frezza E, Booth A, Lotze MT, et al. (1998) Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 227: 398-404.
15. Tangkijvanich P, Thong-Ngam D, Theamboonlers A, Hanvivatvong O, Kullavanijaya P, et al. (2004) Diagnostic role of serum interleukin 6 and CA 19-9 in patients with cholangiocarcinoma. Hepatogastroenterology 51: 15-19.
16. Meng F, Yamagiwa Y, Taffetani S, Han J Patel T (2005) IL-6 activates serum and glucocorticoid kinase via p38alpha mitogen-activated protein kinase pathway. Am J Physiol Cell Physiol 289: C971-C981.
17. Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T (2006) Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res 66: 10517-10524.
18. Meng F, Yamagiwa Y, Ueno Y, Patel T (2006) Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol 44: 1055-1065.
19. Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T (2008) Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 27: 378-386.
20. Braconi C, Meng F, Swenson E, Khrapenko L, Huang N, et al. (2009) Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures. Cancer 115: 3738-3748.
21. Vijapurkar U, Wang W, Herbst R (2007) Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways. Cancer Res 67: 237-245.
22. Chin GM, Herbst R (2006) Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint. Mol Cancer Ther 5: 2580-2591.
23. Gregory J, Kim H, Alonzo T, Gerbing R, Woods W, et al. (2009) Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129. Pediatr Blood Cancer 53: 1005-1010.
24. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, et al. (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317: 121-124.
25. Park EJ, Lee JH, Yu GY, He G, Ali SR, et al. (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140: 197-208.
26. Yamagiwa Y, Meng F Patel T (2006) Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes. Life Sci 78: 2494-2502.
27. Yamagiwa Y, Marienfeld C, Tadlock L, Patel T (2003) Translational regulation by p38 mitogen-activated protein kinase signaling during human cholangiocarcinoma growth. Hepatology 38: 158-166.
28. Tadlock L, Patel T (2001) Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line. Hepatology 33: 43-51.
29. Naugler WE, Karin M (2008) The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14: 109-119.
30. Monteith GR, McAndrew D, Faddy HM, Roberts-Thomson SJ (2007) Calcium and cancer: targeting Ca2+ transport. Nat Rev Cancer 7: 519-530.
31. Coleman CI, Baker WL, Kluger J, White CM (2008) Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens 26: 622-629.
32. Debes JD, Roberts RO, Jacobson DJ, Girman CJ, Lieber MM, et al. (2004) Inverse association between prostate cancer and the use of calcium channel blockers. Cancer Epidemiol Biomarkers Prev 13: 255-259.
33. Olsen JH, Sorensen HT, Friis S, McLaughlin JK, Steffensen FH, et al. (1997) Cancer risk in users of calcium channel blockers. Hypertension 29: 1091-1094.
34. Chiu LY, Ko JL, Lee YJ, Yang TY, Tee YT, et al. (2009) L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett.
35. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935.
36. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.